1-2 of 2
multiple-dose regimen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia

Clinical Trials & Observations
Tadeusz Robak, Maciej Kaźmierczak, Isidro Jarque, Vasile Musteata, Jacek Treliński, Nichola Cooper, Peter Kiessling, Ute Massow, Franz Woltering, Rose Snipes, Juan Ke, Grant Langdon, James B. Bussel, Stephen Jolles
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4136–4146.
https://doi.org/10.1182/bloodadvances.2020002003
Published: 2020
Includes: Supplemental data
Journal Articles

Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies

Clinical Trials & Observations
Alexander Röth, Scott T. Rottinghaus, Anita Hill, Eric S. Bachman, Jin Seok Kim, Hubert Schrezenmeier, Louis Terriou, Álvaro Urbano-Ispizua, Richard A. Wells, Jun Ho Jang, Austin G. Kulasekararaj, Jeff Szer, Rasha Aguzzi, Andrew I. Damokosh, Lori Shafner, Jong Wook Lee
Journal: Blood Advances
Blood Adv (2018) 2 (17): 2176–2185.
https://doi.org/10.1182/bloodadvances.2018020644
Published: 2018
Includes: Supplemental data